



[E-mail this story to a friend](#)

### **Omnia Biologics, Inc. And AT-GC BioPharm, Inc. Form A Strategic Manufacturing Alliance**

ROCKVILLE, Md., March 23 /PRNewswire/ -- Biologics contract manufacturer Omnia Biologics, Inc. (Rockville, MD) and biopharmaceutical technology development company, AT-GC BioPharm, Inc. (Baltimore, MD) today announced the signing of a strategic alliance to develop AT-GC Electronic Eye(TM) technology for the manufacture of biopharmaceutical products. The Electronic Eye platform provides for continuous monitoring of complex processes without having to physically sample and measure individual components. In proof of concept studies real time monitoring has shown improvement in manufacturing processes of up to a log.

"The biopharmaceuticals space continues to be plagued by manufacturing inconsistencies and inefficiencies that would be unacceptable in other industries," commented Dale VanderPutten, CEO, Omnia Biologics. "The Electronic Eye technology is the only technology that we have seen that provides for better than just incremental improvements in biologics manufacture. We are thrilled to work with AT-GC and be the first CMO to offer this exciting technology to our customers."

AT-GC has developed a self-monitoring closed-loop technology that uses non-invasive and non-destructive near infrared and acousto-optical sensors to regulate the manufacturing process in real-time. The technology platform addresses one of the most painful aspects of manufacturing-the capacity crunch-without significant capital investments. Arkesh Mehta, CEO of AT-GC BioPharm is confident that a strategic alliance with Omnia Biologics is validation of AT-GC's technology. The non-invasive and non-destructive real time monitoring technology will allow Omnia Biologics to manufacture quality assured products for their customers.

Under the agreement, AT-GC and Omnia will work together to provide the Electronic Eye technology to customers seeking bioprocessing scale-up, process development, process characterization, and improvements in bioprocessing efficiencies and reproducibility. The work will take place at Omnia's state-of-the-art bioprocessing and cGMP manufacturing facility in Rockville, MD.

About Omnia Biologics: (<http://www.omniabiologics.com/>)

Omnia Biologics (Omnia) is a contract manufacturer focused on the development of innovative biopharmaceutical platforms and technologies. Omnia offers services in the areas of process development, GMP manufacture, and fill-finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

About AT-GC BioPharm: (<http://www.biopharm.at-gc.com/>)

AT-GC Research is a biopharmaceutical process innovation company. AT-GC has developed a proprietary Intelligent Manufacturing Platform for biopharmaceuticals. AT-GC technology platform is a self monitoring closed loop technology that uses non-invasive and non-destructive near infrared and acousto-optical sensors to regulate the manufacturing process in real-time. The technology platform addresses one of the most painful aspects of bio-manufacturing-the capacity crunch-without significant capital investments. The total market for the

biologics manufacturing is expected to be \$30-40 billion. The process development segment is expected to be \$10-15 billion, with more than 50% outsourcing. The technology platform is global regulatory agency (FDA, EMEA and ICH) compliant, with excellent quality assurance and electronic submission components built-in. The management has more than 100 years of combined Brain to Bank management experience in biopharmaceutical industry.

CONTACT: Dale VanderPutten, Chief Executive Officer, of Omnia Biologics, Inc., +1-301-984-5928, Fax: +1-301-984-2515, [dale@omniabiologics.com](mailto:dale@omniabiologics.com); or Jenny Smith, Media Relations Department, Corporate Communications Division, of AT-GC BioPharm, Inc., +1-301-540-5474, Fax: +1-270-447-4777, [jenny@at-gc.com](mailto:jenny@at-gc.com), [PR@at-gc.com](mailto:PR@at-gc.com)  
Omnia Biologics, Inc.

CONTACT: Dale VanderPutten, Chief Executive Officer, of Omnia Biologics, Inc., +1-301-984-5928, Fax: +1-301-984-2515, [dale@omniabiologics.com](mailto:dale@omniabiologics.com); or JennySmith, Media Relations Department, Corporate Communications Division, of AT-GC BioPharm, Inc., +1-301-540-5474, Fax: +1-270-447-4777, [jenny@at-gc.com](mailto:jenny@at-gc.com), [PR@at-gc.com](mailto:PR@at-gc.com)

Web site: <http://www.omniabiologics.com/http://www.biopharm.at-gc.com/>  
(See Story from BioSpace.com) *(03/23/2005)*

#### **Related Companies**

- AT-GC BioPharm, Inc.:  
[Profile, News](#)
- Omnia:
- Omnia Biologics, Inc.:  
[Profile, News](#)